Comparison of candidemia patient profile in COVID-19 and non-COVID-19 cases in a tertiary hospital in Surabaya, Indonesia

Agung Dewi Sekar Langit Partha; Agung Dwi Wahyu Widodo; Muhammad Vitanata Arfijanto

doi:10.53730/ijhs.v6nS4.12243

Authors

Agung Dewi Sekar Langit Partha Department of Clinical Microbiology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Agung Dwi Wahyu Widodo
agungmdimun19@gmail.com
Department of Clinical Microbiology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
Muhammad Vitanata Arfijanto Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

Keywords:

candidemia, Candida sp., COVID-19

Abstract

The COVID-19 pandemic has been linked to secondary infections. Candidemia, a fungal healthcare-associated infection, has been described in patients hospitalized with severe COVID-19. Risk factors for developing severe COVID-19 include older age, malignancies, obesity, immunocompromised conditions, and chronic diseases, many of which are also risk factors for candidemia. This study aimed to compare clinical characteristics of candidemia in patients with and without COVID-19. This retrospective study observe patients medical records from 2020 – 2021 at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. A total of 131 candidemia cases (23 COVID-19 patients and 108 non-COVID-19 patients) were included during the study periods. COVID-19 cases had a higher rate of diabetes (60,9%, p=0,00), pulmonary disease (87%, p=0,00), obesity (34,8%, p=0,00), and having urinary catheter (69,6%, p=0,00). Non-albicans candida was the most common agent of candidemia in non-COVID-19 patients (91,3%, p=0,03). The susceptibility of fluconazole (80,6 v 56,5, p=0,01), caspofungin (82,4 v 60,9, p=0,04), amphotericin B (90,7 v 78,3, p=0,03) and flucytosine (92,6 v 73,9, p=0,00) were higher in non-COVID-19 patients. Based on the study result, it is important to take measures to prevent the transmission of Candida spp. with lower antifungal sensitivity that cause candidemia in COVID-19 patients.

Downloads

Download data is not yet available.

References

Agnelli, C., Valerio, M., Bouza, E., Guinea, J., Sukiennik, T., Guimarães, T., & Colombo, A. L. (2022). Prognostic factors of Candida spp. bloodstream infection in adults: A nine-year retrospective cohort study across tertiary hospitals in Brazil and Spain. The Lancet Regional Health-Americas, 6, 100117

Akbarov, A. N., & Xabilov, D. N. U. (2021). The condition of the oral cavity in patients who have had a viral infection COVID-19. International Journal of Health & Medical Sciences, 4(4), 381-383. https://doi.org/10.21744/ijhms.v4n4.1796

Aquaresta, F., Kawilarang, A. P., & Endraswari, P. D. (2020). Gastric Perforation Associated with Candidiasis and NSAIDS. Indonesian Journal of Tropical and Infectious Disease, 8(3), 168-173.

Asmarawati, T. P., Rosyid, A. N., Suryantoro, S. D., Mahdi, B. A., Windradi, C., Wulaningrum, P. A., ... & Nasronudin, N. (2021). The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya. F1000Research, 10.

Indrasari, D. D., Koendhori, E. B., & Kuntaman, K. (2022). The impact of the COVID-19 pandemic on antimicrobial resistance at Dr. Soetomo Academic Hospital of Surabaya. International Journal of Health Sciences, 6, 1058-1072.

Kayaaslan, B., Eser, F., Kaya Kalem, A., Bilgic, Z., Asilturk, D., Hasanoglu, I., & Guner, R. (2021). Characteristics of candidemia in COVID‐19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non‐COVID‐19 patients. Mycoses, 64(9), 1083-1091.

Mastrangelo, A., Germinario, B. N., Ferrante, M., Frangi, C., Li Voti, R., Muccini, C., & Ripa, M. (2020). Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls. Clin Infect Dis, 30, ciaa1594.

Nathania, E., & Widjaja, J. T. (2021). Candidiasis as Secondary Infection in Post COVID-19: A New Problem?. Jurnal Respirasi, 7(3), 127-133.

Nucci, M., Barreiros, G., Guimarães, L.F., Deriquehem, V. A., Castiñeiras, A. C., & Nouér, S. A. (2021). Increased incidence of candidemia in a tertiary care hospital with the COVID‐19 pandemic. Mycoses, 64(2), 152-156.

Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018). Invasive candidiasis. Nature Reviews Disease Primers, 4(1), 1-20.

Seagle, E. E., Jackson, B. R., Lockhart, S. R., Georgacopoulos, O., Nunnally, N. S., Roland, J., & Lyman, M. M. (2021). The landscape of candidemia during the COVID-19 pandemic. Clinical Infectious Diseases.

Song, G., Liang, G., & Liu, W. (2020). Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia, 1-8.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. International Journal of Health Sciences, 5(2), vi-ix. https://doi.org/10.53730/ijhs.v5n2.2937

Todi, S. (2020). Mycoses in intensive care units. In Clinical Practice of Medical Mycology in Asia (pp. 67-74). Springer, Singapore.

Zhang, W., Song, X., Wu, H., & Zheng, R. (2020). Epidemiology, species distribution, and predictive factors for mortality of candidemia in adult surgical patients. BMC Infectious Diseases, 20(1), 1-11.